Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2/miR-130a-3p-dependent mechanism

Fig. 4

HDAC inhibitor ITF2357 reduces the resistance of mut-KRAS NSCLC cells to Pem by inhibiting HDAC2/Rad51. A RT-qPCR was used to detect the gene expression level of Rad51 in cells upon different treatments. B Western blot was used to detect the protein expression level of Rad51 in cells upon different treatments. C LinkedOmics database was used to analyze the correlation between Rad51 and HDAC2 in TCGA-LUAD. D RT-qPCR was used to detect the gene expression levels of HDAC2 and Rad51 in cells upon different treatments. E Western blot was used to detect the protein expression level of Rad51 in cells upon different treatments. F The viability of cells upon different treatments was detected by MTT. G The migration and invasion of cells upon different treatments were detected by Transwell assay. H The apoptosis of cells upon different treatments was detected by flow cytometry. *p < 0.05. **p < 0.01. ***p < 0.001. ****p < 0.0001. Data among multiple groups were compared by one-way ANOVA, followed by Tukey’s post hoc tests. Cellular experiments were repeated three times

Back to article page